Thera-SAbDab

DROZITUMAB

> Structural Summary

Therapeutic	Drozitumab
Target	TNFRSF10B
Heavy Chain	EVQLVQSGGGVERPGGSLRLSCAASGFTFDDYAMSWVRQAPGKGLEWVSGINWQGGSTGYADSVKGRVTISRDNAKNSLYLQMNSLRAEDTAVYYCAKILGAGRGWYFDYWGKGTTVTVSS
Light Chain	SELTQDPAVSVALGQTVRITCSGDSLRSYYASWYQQKPGQAPVLVIYGANNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCNSADSSGNHVVFGGGTKLTVL
100% seqID Fv Structure	4od2 [Fvs: BA]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	None

100% seqID Structure	4od2 [Fvs: BA]

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (June '19)	Phase-II
Estimated Status (June '19)	Discontinued
Recorded Developmental Technology	na
INN Year Proposed	2010
INN Year Recommended	2011
Companies Involved	Genentech
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Chondrosarcoma, Colorectal cancer, Non-Hodgkin's lymphoma, Non-small cell lung cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]